Slide 1: 2018 nine-month & third-quarter sales
29.10.2018 2018 nine-month & third-quarter sales Webcast presentation for investors, analysts & media Basel, 30 October 2018 Disclaimer This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks,
Slide 2: Highlights
29.10.2018 Highlights Marco Gadola, CEO Another encouraging quarter keeps us on track to deliver our full-year targets REVENUE GROWTH TOP PERFORMERS CHF 989 m +18% organic 1 APAC & NAM Up 23% from 9M 2017 over 9M & in Q3 generate 58% of Group 9M growth; FX effect neutral APAC growing fastest (+33%)
Slide 3: Strong growth trend continues in Q3
29.10.2018 Strong growth trend continues in Q3 EMEA NAM Q3 2018 11.9% Q3 2018 19.5% H1 2018 13.4% H1 2018 18.1% APAC Q3 2018 33.1% H1 2018 28.8% LATAM Q3 2018 13.0% Group H1 2018 20.7% Q3 2018 18.1% H1 2018 17.9% Organic revenue growth 5 Business and regional review Peter Hackel, CFO 3
Slide 4: Double-digit growth in all regions
29.10.2018 Double-digit growth in all regions Revenue development (CHFm, rounded) Regional share of organic growth 23.4% 18.0% CHF organic 10% LATAM 14.3 989.0 43.2 44.3 29% 48.9 APAC 34.1 838.3 801.3 2.9 29% North Change in organic growth America 13.0% 18.6% 30.2% 18.1% 32% EMEA Revenues FX effect
Slide 5: Asia Pacific dynamic; Latin America solid
29.10.2018 Asia Pacific dynamic; Latin America solid APAC Revenue change (organic) China continues to be main 32.5% 33.1% 56% powerhouse; Anthogyr adds to growth 27.9% 25.7% 25.0% Healthy growth in India & Japan 22.1% 19.4% New sales subsidiary in Thailand also 19% of Group contributes to grow
Slide 6: Clear-aligner business growing fast
29.10.2018 Clear-aligner business growing fast +60% Significant case growth in Q3 (+60%) case starts Customer base expands >10% in first 9M Pilot programs completed in Europe – sales force built up with the aim to fully launch in 2019 ClearCorrect well received at Orto 2018 trade fair in Bra
Slide 7: Strategic priorities in place
29.10.2018 Strategic priorities in place DRIVE OUR HIGH TARGET UNEXPLOITED MARKETS BECOME A TOTAL SOLUTION PERFORMANCE CULTURE AND SEGMENTS PROVIDER IN ESTHETIC DENTISTRY 13 Addressing the highly attractive fully-tapered implant segment with Straumann BLX 1 in every 4 implants placed globally is f
Slide 8: BLX key benefits
29.10.2018 BLX key benefits • Perfected for • ‘Cut, Collect, Condense’ • One connection • Trusted premium Swiss immediacy; broad - high bone-to-implant brand • Slim & under- range of indications contact contoured prosthetics • Roxolid® enabling • Business • Designed for optimal 3.75mm diameter for •
Slide 9: Straumann PURE ceramic implant portfolio expanded
29.10.2018 Straumann PURE ceramic implant portfolio expanded New two-piece solution complements existing PURE Monotype design Increases prosthetic flexibility, facilitates handling and is suitable for guided implant placement Designed for optimum esthetics; high-performance ceramic mimics colo
Slide 10: Straumann Emdogain supply resumed in the US
29.10.2018 Straumann Emdogain supply resumed in the US Change at manufacturing facility approved by FDA Unique product with proven regenerative properties >2 million patients treated in past 22 years Gold standard for inducing safe and predictable regeneration of lost periodontal tissue Po
Slide 11: New Group subsidiary opens in Lima, Peru
29.10.2018 New Group subsidiary opens in Lima, Peru Sixth Group subsidiary in LATAM went into operation on 28 August 2018 Addresses premium and non-premium segments in a fast-growing market Launch of Neodent’s new implant system Grand Morse announced Straumann brand launch expected in Q4 P
Slide 12: 2018 outlook raised
29.10.2018 2018 outlook raised Barring unforeseen circumstances Market Global implant market expected to grow 4-5% Our revenue Full-year organic revenue growth growth in the high-teen percentage range Further improvement in EBITDA margin; Profitability1 EBIT margin stable 23 1 Excluding exceptional
Slide 13: Convincing growth drivers for the coming years
29.10.2018 Convincing growth drivers for the coming years Preventive dentistry could add up to Growth CHF 2bn to Group’s addressable potential market Preventive dentistry Expansion into esthetic dentistry Preventive Implantology Address unexploited Clear markets and segments Aligners Biomaterials Ma
Slide 14: Questions & answers
29.10.2018 Questions & answers & 12th edition of ‘Analyst Talk’ feat. BNP Exane Paribas From left to right: Marco Gadola, Straumann Group CEO, Julien Dormois, senior analyst at Exane BNP Paribas 28 14
Slide 15: Calendar of upcoming events
29.10.2018 Calendar of upcoming events 2018 Event Location 30 October Q3 results webcast Webcast 05 November Corporate Governance meetings Zurich 15 November Credit-Suisse Swiss Midcap conference Zurich 05 December Berenberg equities conference Pennyhill (UK) 13 December Corporate Governance meeting
Slide 16: Straumann's currency exposure
29.10.2018 Straumann’s currency exposure Revenue breakdown FY20171 FX sensitivity CHF Average exchange rates (rounded) (+/- 10%) on full-year... Other 9% 14% 2017 H1 2018 9M 2018 Revenue EBIT BRL 1 EURCHF 1.09 1.17 1.16 +/- 35m +/- 21m 10% 1 USDCHF 0.99 0.97 0.97 +/- 29m +/- 14m EUR JPY 31% 100 BRLC